• 1
    Beasley RP, Lin C-C, Hwang LY, Chen C.-S. Hepatocellular carcinoma and hepatitis B vims: a prospective study of 22,707 men in Taiwan. Lancet 1981; 2: 11291133.
  • 2
    Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 2960.
  • 3
    Perrillo RP. Antiviral therapy of chronic hepatitis B: past, present and future. J Hepatol 1993; 17 (S3): 5663.
  • 4
    Guidotti LG, Ishikava T, Hobbs MV, Matzke B, Schreiber RD, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 2536.
  • 5
    Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, Pilli M, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991; 88: 214222.
  • 6
    Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello A, et al. HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150: 46594671.
  • 7
    Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, et al. Cytotoxic T lymphocytes recognize an HLA-A2–restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174: 15651570.
  • 8
    Rehermann B, Chisari FV. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 10471058.
  • 9
    Ferrari C, Penna A, Bertoletti A, Valli A, Antoni A Degli, Giuberti T, Cavalli A, et al. Cellular immune response to hepatitis B virus–encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 34423449.
  • 10
    Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub D, et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995; 69: 33583368.
  • 11
    Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, et al. Development of a lipopeptide-based vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995; 1: 341349.
  • 12
    Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Missale G, Fowler P, et al. Definition of an optimal cytotoxic T cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 1993; 67: 23762380.
  • 13
    Del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995; 154: 685693.
  • 14
    Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74: 929937.
  • 15
    Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993; 75: 693706.
  • 16
    Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994; 180: 933943.
  • 17
    Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Fiaccadori F, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonist for antiviral cytotoxic T cells. Nature 1994; 369: 407410.
  • 18
    Fernandez-Vina MA, Falco M, Sun Y, Stastny P. DNA typing for class I alleles: I. Subsets of HLA-A2 and of -A28. Hum Immunol 1992; 33: 163173.
  • 19
    Barouch D, Friede T, Stevanovic S, Tussey L, Smith K, Rowland-Jones S, Braud V, et al. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med 1995; 182: 18471856.
  • 20
    Rotzschke O, Falk K, Stevanovic S, Jung G, Rammense HG. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur J Immunol 1992; 22: 24532456.
  • 21
    Teng JMC, Hogan KT. Both major and minor peptide-binding pockets in HLA-A2 influence the presentation of influenza virus matrix peptide to cytotoxic T lymphocytes. Mol Immunol 1994; 31: 459470.
  • 22
    Tussey LG, Matsui M, Rowland-Jones S, Warburton R, Frelinger JA, McMichael A. Analysis of mutant HLA-A2 molecules. Differential effects on peptide binding and CTL recognition. J Immunol 1994; 152: 12131221.
  • 23
    Hogan KT, Clayberger C, Le AT, Walk SF, Ridge JP, Parham P, Krensky AM, et al. Cytotoxic T lymphocyte-defined epitope differences between HLA-A2.1 and HLA-A2.2 map to two distinct regions of the molecule. J Immunol 1988; 141: 40054011.
  • 24
    Matsui M, Moots RJ, McMichael AJ, Frelinger JA. Significance of the six peptide-binding pockets of HLA-A2.1 in influenza A matrix peptide-specific cytotoxic T-lymphocyte reactivity. Hum Immunol 1994; 41: 160166.
  • 25
    McMichael A, Gotch FM, Santos-Aguado J, Strominger J. Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1988; 85: 91949198.
  • 26
    Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, et al. Long lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 11851194.
  • 27
    Doherty PC, Allan W, Eichelberger M, Carding SR. Role of ab and gd T cell subsets in viral immunity. Annu Rev Immunol 1992; 10: 123151.
  • 28
    Gotch F, Rothbard J, Howland K, Townsend A, McMichael A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987; 326: 881882.
  • 29
    Fremont DH, Matsumura M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992; 257: 919927.
  • 30
    Levitsky V, Zhang Q-J, Levitskaya J, Masucci MG. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med 1996; 183: 915926.
  • 31
    Ferrari C, Bertoletti A, Fiaccadori F, Chisari FV. Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance? Semin Virol 1996; 7: 2330.
  • 32
    Kersh GJ, Allen PM. Essential flexibility in the T-cell recognition of antigen. Nature 1996; 380: 495498.
  • 33
    Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993; 363: 156159.
  • 34
    Jameson SC, Carbone FR, Bevan MJ. Clone-specific T cell receptor antagonists of major histocompatibility complex class I–restricted cytotoxic T cells. J Exp Med 1993; 177: 15411550.
  • 35
    Krausa P, Brywka M III, Savage D, Hui KM, Bunce M, Ngai JLF, Teo DLT, et al. Genetic polymorphism within HLA-A02: significance of allelic variants within different populations. Tissue Antigens 1995; 45: 223231.
  • 36
    Sudo T, Kamikawaji N, Kimura A, Date Y, Savoie CJ, Nakashima H, Furuichi E, et al. Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol 1995; 155: 47494756.
  • 37
    Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J Immunol 1996; 156: 38823891.
  • 38
    Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med 1993; 178: 879887.
  • 39
    Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241251.
  • 40
    von Herrath MG, Yokoyama M, Dockter J, Oldstone MBA, Whitton JL. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol 1995; 70: 10721079.